Oncology Institute, Inc. (TOI)

The Oncology Institute's stock experienced several events in the past six months. Q3 2025 earnings release showed strong revenue growth but a net loss, causing the stock to fall. A preliminary 2026 financial outlook projected revenue growth but limited profitability, leading to a negative investor reaction. Leadership changes were announced. The stock price increased significantly over the past year but has been volatile. A buy signal was issued from a pivot bottom point, leading to a stock increase. Insider sentiment has been negative due to open-market selling from key executives.

Specific demand seasonality for The Oncology Institute's products and services is not explicitly detailed in the provided information. Oncology forecasting is complex due to factors such as specific patient populations, biomarkers, tumor types, and the rapidly evolving landscape of treatments and competitive offerings, rather than seasonal demand fluctuations. Industry-wide, the demand for radiation therapy was projected to increase, but at a slower rate than the supply of radiation oncologists between 2015 and 2025, with an overall reduction in the use of radiation to treat cancer.

The Oncology Institute, Inc. (TOI) operates in the Healthcare sector, focusing on value-based cancer care in community settings. Its services include patient care (oncology, hematology, infusion centers, blood transfusions, physician services, radiation, stem cell transplants, and support services), a retail pharmacy and dispensary for high-cost oral oncology drugs, and clinical trials management.

Founded in 2007 in Cerritos, California, The Oncology Institute has expanded to over 100 clinics and affiliate locations across five states, serving approximately 1.9 million patients. Key markets include Florida, California, and Nevada.

The Oncology Institute's brand reputation is built on its mission to heal and empower patients through compassion, innovation, and state-of-the-art medical care. The company aims to be the nation's leading value-based oncology group, emphasizing high-quality, cost-effective care and driving innovation in cancer treatment. Its core values include unwavering integrity, striving for excellence, working together, and genuine empathy. No specific events negatively impacting TOI's brand reputation in the past year were found, beyond the general market reactions to financial performance and outlook.

The ownership of The Oncology Institute, Inc. is diversified, with individual investors holding the largest stake at approximately 47% and institutional investors holding about 35%. Major institutional owners include Vanguard Group Inc. and BlackRock, Inc. M33 Growth, LLC, a private equity firm, holds a significant stake of 9.1%.